Question 1

Does Cyagen offer customization options for specific metabolic pathways or receptor modifications that might be relevant to drug targets?

Accepted Answer

Yes, Cyagen offers customization options for specific metabolic pathways or receptor modifications tailored to individual research needs. Researchers can request specific genetic modifications that align with their drug targets, facilitating more relevant studies on drug efficacy and mechanisms of action related to those pathways.

Question 2

What biomarker panels have been validated in Cyagen models, particularly for early-stage metabolic dysfunction detection?

Accepted Answer

Cyagen has validated several biomarker panels in their metabolic disease models for early detection of metabolic dysfunction. These panels include biomarkers associated with insulin sensitivity, lipid metabolism, and inflammatory responses, which are crucial for identifying early signs of metabolic disorders.

Question 3

Have any published studies used Cyagen models for testing currently approved metabolic disease drugs, and if so, how did the efficacy results compare to known human clinical outcomes?

Accepted Answer

Yes, several studies have utilized Cyagen's models to test currently approved metabolic disease drugs. The efficacy results from these studies have been shown to correlate well with known human clinical outcomes, reinforcing the relevance of these animal models in preclinical drug testing.

Question 4

Does Cyagen models exhibit the key comorbidities associated with metabolic syndrome (cardiovascular complications, hepatic steatosis, inflammation) that we typically see in human patients?

Accepted Answer

Yes, Cyagen's metabolic disease models exhibit key comorbidities associated with metabolic syndrome, including:
Cardiovascular Complications: Models designed to study atherosclerosis and cardiovascular diseases linked to metabolic disorders.
Hepatic Steatosis: Models reflect conditions like metabolic dysfunction-associated steatotic liver disease (MASLD), including inflammation and fibrosis.
Inflammation: Models incorporate inflammatory responses typical of metabolic syndrome, crucial for understanding liver-related complications.
These features make Cyagen's models valuable for studying the interactions of metabolic syndrome and its comorbidities.

Question 5

What specific genetic modifications have been incorporated into Cyagen models to replicate the polygenic nature of human metabolic disorders?

Accepted Answer

Cyagen incorporates various genetic modifications in their mouse models to mimic the polygenic nature of human metabolic disorders. Examples include:
Ldlr KO (em): Used for studying familial hypercholesterolemia.
Lep KO (ob/ob): Models type 2 diabetes and obesity.
Uox KO: Relevant for hyperuricemia studies.
These modifications allow for the exploration of complex genetic interactions that contribute to conditions like obesity and diabetes.

Question 6

What phenotypic validation data does Cyagen have demonstrating the stability of metabolic parameters (insulin resistance, glucose tolerance, lipid profiles) across different generations?

Accepted Answer

Cyagen's metabolic disease models consistently stabilize key metabolic parameters, such as insulin resistance, glucose tolerance, and lipid profiles, across different generations. This stability is validated through rigorous testing protocols that ensure reliable results for preclinical research and drug development.

Catalog Number	Name	Base Strain	Research Application
C001849	Alpl KO	C57BL/6JCya	Research on hypophosphatasia (HPP); Research on osteoporosis; Research on osteosarcoma (OS).
C001889	Acute PKD (inducible)	C57BL/6N;6JCya	Research on renal tubular calcium homeostasis and mechanotransduction; Research on renal tubular structure, function, and signal transduction; Research on autosomal dominant polycystic kidney disease (ADPKD); Research on other renal diseases.
C001703	Agxt KO	C57BL/6NCya	Studies of glyoxylate metabolism regulation; Primary Hyperoxaluria pathogenesis and therapeutic drug evaluation.
C001267	Atp7b KO	C57BL/6NCya	Copper Metabolism Research; Wilson’s Disease Research; Acute Liver Failure Research; Steatohepatitis Research; Other Research Related to Copper Metabolism Disorders.
C001919	B6-huCFB/hMASP2	C57BL/6Cya	Screening, development, and evaluation of CFB/MASP2-targeted drugs; Research on the pathological mechanisms and treatment methods of immune-related diseases such as age-related macular degeneration (AMD), atypical hemolytic uremic syndrome (aHUS), and systemic lupus erythematosus (SLE); Research on infectious diseases.
C001911	B6-huALK7 (huACVR1C)	C57BL/6NCya	ACVR1C-targeted drug screening, development, and evaluation; Research on the pathological mechanisms and therapeutic approaches of metabolic disorders such as obesity and type 2 diabetes; Research on the pathological mechanisms and therapeutic approaches of certain cancers like retinoblastoma.
C001617	B6-hPCSK9	C57BL/6NCya	Development and screening of PCSK9-targeted therapies； Preclinical pharmacological and efficacy evaluation of PCSK9-targeted therapies； Research on metabolic diseases such as hypercholesterolemia, atherosclerosis, and coronary heart disease； Research on neurodegenerative diseases such as stroke and Alzheimer's disease.
C001522	B6-hLPA (CKI) /Alb-cre	C57BL/6NCya	Research on atherosclerosis, hyperlipidemia, thrombotic cardiovascular diseases, etc; Preclinical evaluation of human LPA-targeted drugs.
I002079	B6-hLPA(CKI)/Alb-cre/hPCSK9	C57BL/6NCya	Hyperlipidemia, stroke, coronary heart disease, familial hypercholesterolemia (FH), and other atherosclerotic cardiovascular diseases (ASCVD); Development and evaluation of targeted drugs against human Lp (a) and PCSK9.
C001553	B6-RCL-hLPA/Alb-cre/TG (APOB)	C57BL/6Cya	Development and evaluation of LP(a) and ApoB targeted drugs; Research on familial hypercholesterolemia (FH); Research on atherosclerotic cardiovascular disease (ASCVD); Research on other cardiovascular diseases (CVD).